AtaiBeckley (ATAI) Operating Margin (2021 - 2026)
AtaiBeckley (ATAI) posted quarterly Operating Margin of 3239.1% for Q1 2026, down 192913.0% year-over-year from N/an in Q1 2025, and down 147.27% quarter-over-quarter from 1309.97% in Q1 2025.
AtaiBeckley (ATAI) Operating Margin (2021 - 2026) Analysis & Trends
AtaiBeckley has reported Operating Margin for 5 years, with the latest figure at 3796.53% in Q3 2025.
- Quarterly Operating Margin rose 5270847.0% year-over-year to 3796.53% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 3438.02% (up 2857920.0% YoY) and the FY2024 annual result came in at 33341.23%, up 661768.0% from the prior year.
- Operating Margin for Q1 2026 stood at 3239.1%, down from 1309.97% in the prior quarter.
- The five-year high for Operating Margin was 1309.97% in Q1 2025, with the low at 3239.1% in Q1 2026.
- A 5-year average of 60266.07% and a median of 20219.77% in 2021 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2023: Operating Margin sank 14755410 bps in 2022, then surged 12925216 bps in 2023.
- Over 5 years, Operating Margin stood at 19641.3% in 2021, then tumbled by 403 bps to 98855.26% in 2022, then sank by 89 bps to 186450.0% in 2023, then tumbled by 35 bps to 252208.33% in 2024, then surged by 98 bps to 3796.53% in 2025.
- According to Business Quant data, Operating Margin over the past three periods registered 3796.53%, 3515.02%, and 1309.97% for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | AtaiBeckley | 2.69 Bn | 2.69 Bn | - | -3,796.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,590.43% |
| Mar 31, 2026 | -3,239.10% |
| Sep 30, 2025 | -3,796.53% |
| Jun 30, 2025 | -3,515.02% |
| Mar 31, 2025 | -1,309.97% |
| Mar 31, 2025 | -1,309.97% |
| Dec 31, 2024 | -252,208.33% |
| Sep 30, 2024 | -56,505.00% |
| Jun 30, 2024 | -9,424.54% |
| Dec 31, 2023 | -186,450.00% |
| Sep 30, 2023 | -30,843.68% |
| Jun 30, 2023 | -18,524.42% |
| Mar 31, 2023 | -89,767.57% |
| Dec 31, 2022 | -98,855.26% |
| Sep 30, 2022 | -160,095.83% |
| Jun 30, 2022 | -20,798.24% |
| Dec 31, 2021 | -19,641.30% |
| Sep 30, 2021 | -12,541.73% |
| Mar 31, 2021 | 20.37% |